Literature DB >> 3061785

Insulin degradation: mechanisms, products, and significance.

W C Duckworth1.   

Abstract

Although much remains to be learned, our understanding of the mechanisms and processes by which insulin is degraded has advanced considerably over the past few years. The roles of receptor binding and internalization in mediating insulin degradation have been clarified, and the endosomal pathway for intracellular insulin degradation has been established and partially characterized. The importance of IP (IDE) in cellular insulin degradation has been established and the importance of lysosomal degradation questioned. Studies on IP have identified the degradation products resulting from insulin metabolism by this enzyme and shown that the degradation products by IP are identical with those produced by isolated hepatocytes. A major remaining question for future investigation is the potential role of insulin degradation and intracellular processing in insulin action.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3061785     DOI: 10.1210/edrv-9-3-319

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  58 in total

1.  Disorders of glucose metabolism: post mortem analyses in forensic cases--part II.

Authors:  Frank Musshoff; Cornelius Hess; Burkhard Madea
Journal:  Int J Legal Med       Date:  2010-10-07       Impact factor: 2.686

Review 2.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

3.  Fate of injected glucagon taken up by rat liver in vivo. Degradation of internalized ligand in the endosomal compartment.

Authors:  F Authier; M Janicot; F Lederer; B Desbuquois
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

4.  An unusual active site identified in a family of zinc metalloendopeptidases.

Authors:  A B Becker; R A Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

5.  Characterization of the bacterial metalloendopeptidase pitrilysin by use of a continuous fluorescence assay.

Authors:  A Anastasi; C G Knight; A J Barrett
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

Review 6.  Principles of drug administration in renal insufficiency.

Authors:  Y W Lam; S Banerji; C Hatfield; R L Talbert
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 7.  Updates on the management of diabetes in dialysis patients.

Authors:  Connie M Rhee; Angela M Leung; Csaba P Kovesdy; Katherine E Lynch; Gregory A Brent; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2014-03       Impact factor: 3.455

Review 8.  Clinical pharmacokinetics and pharmacodynamics of insulin aspart.

Authors:  A Lindholm; L V Jacobsen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Insulin-degrading enzyme in a human colon adenocarcinoma cell line (Caco-2).

Authors:  J P Bai; M J Hsu; W T Shier
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

10.  Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.

Authors:  Christina Yfanti; Karin Mengele; Apostolos Gkazepis; Gregor Weirich; Cecylia Giersig; Wen-Liang Kuo; Wei-Jen Tang; Marsha Rosner; Manfred Schmitt
Journal:  Int J Mol Med       Date:  2008-10       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.